real-time news and commentary for investors
Tuesday, Apr 23
Celsion Corp (CLSN) is moving higher in pre-trading on comments from the company that its...
Celsion Corp (CLSN) is moving higher in pre-trading on comments from the company that its experimental cancer drug, Thermodox, shows it may now in fact be viable for the treatment of liver cancer. The comments come just months after the company warned of the drug's limited prospects, causing the stock to crater 81% in one day in January after the company suggested the drug failed to significantly slow the progression of liver cancer in a late-stage trial. Shares +14%.